Share Name Share Symbol Market Type Share ISIN Share Description
Ekf Diagnostics LSE:EKF London Ordinary Share GB0031509804 ORD 1P
  Price Change % Change Share Price Shares Traded Last Trade
  +0.05p +0.18% 27.70p 261,275 16:35:04
Bid Price Offer Price High Price Low Price Open Price
27.20p 28.20p - - -
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Health Care Equipment & Services 41.58 4.31 59.00 0.5 126.8

Ekf Diagnostics (EKF) Latest News

More Ekf Diagnostics News
Ekf Diagnostics Takeover Rumours

Ekf Diagnostics (EKF) Share Charts

1 Year Ekf Diagnostics Chart

1 Year Ekf Diagnostics Chart

1 Month Ekf Diagnostics Chart

1 Month Ekf Diagnostics Chart

Intraday Ekf Diagnostics Chart

Intraday Ekf Diagnostics Chart

Ekf Diagnostics (EKF) Discussions and Chat

Ekf Diagnostics (EKF) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
15:10:2027.304,5661,246.52O
14:21:3227.304,0001,092.00O
11:28:0728.00250,00070,000.00O
10:26:3227.25450122.63O
08:00:4327.252,259615.58O
View all Ekf Diagnostics trades in real-time

Ekf Diagnostics (EKF) Top Chat Posts

DateSubject
12/11/2018
08:20
Ekf Diagnostics Daily Update: Ekf Diagnostics is listed in the Health Care Equipment & Services sector of the London Stock Exchange with ticker EKF. The last closing price for Ekf Diagnostics was 27.65p.
Ekf Diagnostics has a 4 week average price of 25.90p and a 12 week average price of 25.90p.
The 1 year high share price is 41.10p while the 1 year low share price is currently 22.60p.
There are currently 457,632,749 shares in issue and the average daily traded volume is 998,742 shares. The market capitalisation of Ekf Diagnostics is £126,535,455.10.
28/10/2018
06:56
wan: Cambridgedon...If we take 40p (Market cap £183m) as having fully realised, in share price terms, the soluble Tumor Necrosis Factor Receptors 1 and 2 (sTNFR1/2) biomarker assets, and then factor in EKF receiving in round figures £25m (20,964,524 RENX Shares @ £1.21) for those assets, that should result in a ex distribution share price (reduction) to circa 35p (market cap £160m) However, 40p may have been driven by increased demand ahead of the spin-out, but even if we targeted 35p as discounting the effects of such demand, then we would arrive at an ex distribution share price of 30p (hence previous comments) From the point of announcing the spin-out (11th Jan 2018 share price circa 26p), if one looks at specific announcements and other stated growth initiatives, which are over and above that associated with Renaltix, then there is very good reason to expect an increase in organic growth over the near term and a significant increase in growth over the medium term.
23/10/2018
14:34
wan: Macarona...As discussed on here previously, the current EKF share price appears to have already reflected the distribution, presumably because the announcements had effectively flagged when and by how much, but as I said this morning, time will tell None of us can predict what will happen when Renalytix commences trading, but having done quite a bit of research I am quite hopeful about the near to medium term prospects for Renalytix (including potential news flow), and maybe there will be good demand for the shares (other AI in healthcare companies are certainly attaining very high valuations). So my decision to buy more EKF shares was based on the current share price pullback and the near term prospects and potential news flow for EKF, and also about getting the maximum exposure to Renalytix ahead of any high demand and potentially being scaled back on the Restricted Offer, via which I intend to also add (and possibly when trading commences too). Best wishes to all EKF and Renalytix shareholders.
23/10/2018
07:13
cambridgedon: Hi All, Thanks Wan. The ratio of new shares to old is a little better than we originally calculated. Surprised at the record date but not complaining as added recently. I'll be happier when the EKF price gets back to the high 30's where it should be all things considered. CD
20/10/2018
07:32
wan: Cambridgedon...As I said previously, there is a lot to digest! I assume we will know early next week regarding the de minimis threshold, but one assumes that what ever that threshold is, it will then be based on a round number. There are 457,554,636 shares in issue, which in your scenario would be closer to 45 or 46 shares per 1000 EKF shares. As Ingroid suggests, the current EKF share price does appear to reflect the distribution (as per the case when a stock goes ex dividend), but you will have to wait six months to ultimately realise it (if you wanted to sell). Personally speaking, I was not looking to immediately sell the Renalytix shares anyway (as I had good reasons to think that the investment prospect would be a good one), so I am not fazed by the lock-up period. I note Renalytix will also pay back all the EKF loans, so there is some cash to come back too. Overall, I am very impressed with the know-how and expertise behind Renalytix, including how they have assessed the proposition and positioned Renalytix to address the market, which is indeed very large (as are the resulting savings and resultant business proposition). EKF clearly see a good investment proposition too, as they intend to take part in the fund raise and have a notifiable interest in Renalytix. Renalytix aside, I still think that EKF is an excellent long term investment.
16/10/2018
11:59
ingroid: Share price now ex distribution.Have copy of documents for the restricted shares and as far as i see you attach a cheque and apply for equivalent number of shares. It will be left to you . Obviously if oversubscribed you will be scaled back accordingly.
16/10/2018
09:50
cambridgedon: Don't bother to call the "helpline", they have not even heard of EKF nor Renalytix AI! I've told N+1 Singer who were not impressed. From what I can gather the ratio of free shares to your existing holding will not be known until after the GM on Friday or some other later date. As to how many new shares you can subscribe for at £1.21, should you wish, I've no idea. If Wan or anyone else can shed some light on all of this I'd be grateful. Also, the share price keeps heading lower too. All very odd. CD
27/9/2018
06:56
wan: I note yesterday that Peel Hunt has initiated coverage of Sensyne Health Plc Ord 10p [LON:SENS] with a buy investment rating and price target of 261p. Current share price is 198p. I have highlighted Sensyne previously, Sensyne combines experience in AI, digital health and life sciences.
09/4/2018
08:28
wan: N+1 Singer analyst Chris Glasper has published commentary today in which he described news from EKF of FDA 510k approval and CLIA Waiver as “very positive news” and asserts that “the potential opportunity is material for EKF”, with a “$35m+ market for point of care testing in the US to go at”. Forecasts remain unchanged at the moment but he writes: “We make no changes to our estimates, pending confirmation of the commercial strategy, which we expect in the coming months. We continue to see meaningful upside to the current share price on this and other opportunities in the pipeline.” N+1 Singer currently forecast £43.4m revenue for 2018, adj EBITDA of £10m and £7.5m adj PBT. For 2019 these rise to £44.7m, adj EBITDA of £10.8m and adj PBT of £8.0m. (END) Indeed I concur ;-) I also see material upside.
20/7/2016
10:58
andrewbaker: The recent share purchase (see news articles on quotes page) suggests that the company is prospering/will prosper greatly going forward. The weakness of the £ sterling combined with sales in US$ and other currencies is a big boost for many British businesses; and if their core product(s) are improving in sales/prospects too, that's a double bonus. A continuing rise in the EKF share price looks very much on the cards right now and going forward.
08/5/2014
09:20
totaleclipse: Just to put in a tiny bit more information I heard that Selah sales people were being paid very high commissions per test to incentivize them. Like half! That's kind of excessive dont you think? If the reimbursers discovered that bit of information I would guess they would be less than happy as it suggests the margins are very wide and maybe the reason for the cut. >>Bigman. You spotted a good point. If we focus on the next driver for the EKF share price- i.e. the 6 months results, the sales will be enhanced by just the $0.5m you calculate for April and a further $1.5m for May and June- not sure if that is going to reignite the shares to recover their upward path. Anyone have any views on the 6 month numbers?
Ekf Diagnostics share price data is direct from the London Stock Exchange
add chat code
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:40 V: D:20181112 17:33:07